Back to GetFilings.com



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q

Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
  For the quarterly period ended November 2, 2002 or
   
Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
  For the transition period from         to

Commission File Number 1-4311

PALL CORPORATION
(Exact name of registrant as specified in its charter)

New York
(State or other jurisdiction of
incorporation or organization)
11-1541330
(I.R.S. Employer
Identification No.)
 
2200 Northern Boulevard, East Hills, NY
(Address of principal executive offices)
  11548
(Zip Code)
     
(516) 484–5400
(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrant was required to file such reports), and (2) has been subject to such filing requirement for the past 90 days. Yes No

The number of shares of the registrant’s common stock outstanding as of December 6, 2002 was 122,973,348.

 


TABLE OF CONTENTS

   
Page No.
PART I. FINANCIAL INFORMATION  
Item 1. Financial Statements  
 
 
 
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations. 13
Item 4. Controls and Procedures 18
   
PART II.  OTHER INFORMATION  
Item 1. Legal Proceedings. 18
Item 6. Exhibits and Reports on Form 8-K. 19

SIGNATURES 20

 

 

2


PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

PALL CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except per share data)
(Unaudited)

    Nov. 2, 2002     Aug. 3, 2002  
 

 

 
ASSETS
           
Current assets:            
Cash and cash equivalents
$ 90,507   $ 105,224  
Short-term investments
  22,600     40,200  
Accounts receivable, net
  364,293     415,853  
Inventories
  279,832     256,910  
Other current assets
  82,111     97,795  
 

 

 
Total current assets
  839,343     915,982  
Property, plant and equipment, net   599,587     605,095  
Goodwill, net   226,101     262,973  
Intangible assets, net   55,338     39,948  
Other assets   194,850     203,224  
 

 

 
Total assets
$ 1,915,219   $ 2,027,222  
 

 

 
LIABILITIES AND STOCKHOLDERS’ EQUITY            
Current liabilities:            
Notes payable to banks
$ 14,095   $ 42,202  
Accounts payable and other current liabilities
  264,384     293,076  
Income taxes
  29,471     41,549  
Current portion of long-term debt
  56,656     61,344  
 

 

 
Total current liabilities
  364,606     438,171  
Long-term debt, net of current portion   617,904     619,705  
Deferred taxes and other non-current liabilities   144,628     149,626  
 

 

 
Total liabilities
  1,127,138     1,207,502  
 

 

 
Stockholders’ equity:            
Common stock, par value $.10 per share
  12,796     12,796  
Capital in excess of par value
  110,409     110,745  
Retained earnings
  797,954     832,308  
Treasury stock, at cost
  (109,773 )   (110,799 )
Stock option loans
  (2,695 )   (3,259 )
Accumulated other comprehensive loss:
           
Foreign currency translation
  (13,768 )   (17,429 )
Minimum pension liability
  (3,075 )   (3,079 )
Unrealized investment losses
  (2,705 )   (236 )
Unrealized losses on derivatives
  (1,062 )   (1,327 )
 

 

 
    (20,610 )   (22,071 )
 

 

 
Total stockholders’ equity   788,081     819,720  
 

 

 
Total liabilities and stockholders’ equity $ 1,915,219   $ 2,027,222  
 

 

 

See accompanying notes to condensed consolidated financial statements.

 

3


PALL CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share data)
(Unaudited)

    Three Months Ended  
 

 
    Nov. 2, 2002     Oct. 27, 2001  
 

 

 
Net sales $ 332,210   $ 274,119  
Cost of sales   174,261     135,070  
 

 

 
Gross profit   157,949     139,049  
Selling, general and administrative expenses   116,860     98,074  
Research and development   13,045     12,847  
Restructuring and other charges   40,375      
Interest expense, net   7,266     3,263  
 

 

 
(Loss) earnings before income taxes   (19,597 )   24,865  
Income taxes   3,541     5,473  
 

 

 
Net (loss) earnings $ (23,138 ) $ 19,392  
 

 

 
(Loss) earnings per share:            
Basic
$ (0.19 ) $ 0.16  
Diluted
$ (0.19 ) $ 0.16  
             
Dividends declared per share $ 0.09   $ 0.17  
Average shares outstanding:            
Basic
  122,825     122,190  
Diluted
  122,825     123,486  

See accompanying notes to condensed consolidated financial statements.

 

4


PALL CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
(Unaudited)

    Three Months Ended  
 

 
    Nov. 2, 2002     Oct. 27, 2001  
 

 

 
Net cash provided by operating activities, net of effect of acquisitions $ 34,795   $ 16,614  
Investing activities:            
Acquisitions of businesses   (7,999 )    
Capital expenditures   (14,456 )   (19,374 )
Disposals of fixed assets   1,118     595  
Short-term investments   17,600     71,400  
 

 

 
Net cash (used) provided by investing activities   (3,737 )   52,621  
 

 

 
Financing activities:            
Notes payable   (379,099 )   (14,786 )
Long-term borrowings   380,004     1,497  
Repayments of long-term debt   (37,236 )   (31,711 )
Net proceeds from stock plans   1,148     3,192  
Purchase of treasury stock       (9,999 )
Dividends paid   (11,049 )   (20,808 )
 

 

 
Net cash used by financing activities   (46,232 )   (72,615 )
 

 

 
Cash flow for period   (15,174 )   (3,380 )
Cash and cash equivalents at beginning of year   105,224     54,927  
Effect of exchange rate changes on cash   457     172  
 

 

 
Cash and cash equivalents at end of period $ 90,507   $ 51,719  
 

 

 
Supplemental disclosures:            
Interest paid
$ 5,125   $ 7,511  
Income taxes paid (net of refunds)
  8,234     11,103  

See accompanying notes to condensed consolidated financial statements.

 

5


PALL CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(In thousands, except per share data)
(Unaudited)

NOTE 1 – BASIS OF PRESENTATION

The financial information included herein is unaudited. However, such information reflects all adjustments which are, in the opinion of management, necessary to present fairly the Company’s financial position, results of operations and cash flows as of the dates and for the periods presented herein. These financial statements should be read in conjunction with the financial statements and notes set forth in the Company’s Annual Report on Form 10-K for the fiscal year ended August 3, 2002.

NOTE 2 – ACQUISITION

On April 24, 2002, the Company acquired the Filtration and Separations Group (“FSG”) from United States Filter Corporation (“US Filter”) for $360,000 in cash, subject to a post closing adjustment of the purchase price based on the net assets acquired as of April 27, 2002. The adjustment to the purchase price was finalized in the first quarter of fiscal 2003, resulting in additional consideration due to US Filter of $7,801. The operating results of FSG are reported in the Company’s results of operations from April 28, 2002.

The acquisition was accounted for using the purchase method of accounting in accordance with SFAS No. 141, Business Combinations (“SFAS No. 141”). SFAS No. 141 requires that the total cost of the acquisition be allocated to the tangible and intangible assets acquired and liabilities assumed based upon their respective fair values at the date of acquisition. The allocation of the purchase price is dependent upon certain valuations and other studies. In the first quarter of fiscal 2003, the valuation of in-process research and development and certain amortizable intangible assets, patented and unpatented technology, was finalized. As a result, the Company wrote-off $37,600 of preliminary goodwill as in-process research and development and reallocated $16,800 of preliminary goodwill to write up the aforementioned amortizable intangible assets from their book value to their fair value of $20,100 (please refer to Note 3 for further discussion). The amount of in-process research and development was determined by identifying research projects for which technological feasibility had not been established and for which no alternative future uses existed. As of the acquisition date, there were various projects that met the above criteria. The majority of the projects identified are targeted for the General Industrial segment.

The value of the research projects identified to be in process was determined by estimating the future cash flows from the projects once commercially feasible, discounting the net cash flows back to their present value and then applying a percentage of completion to the calculated value. The key assumptions specifically underlying the valuation for purchased in-process research and development consist of an expected completion date for the in-process projects, estimated costs to complete the projects, revenue and expense projections, and discount rates based on the risks associated with the development life cycle of the in-process technology acquired. The weighted average discount rate used was approximately 24% (ranging from 18% to 67%). The percentage of completion for the projects was determined using milestones representing estimates of effort, value added and degree of difficulty of the portion of the projects completed as of April 27, 2002, as compared to the total research and development to be completed to bring the projects to technological feasibility. As of April 27, 2002, the Company estimates the projects were approximately 67% complete on a weighted average basis (ranging from 2% to 96%).

The development of these technologies remains an uncertainty due to the remaining efforts to achieve technological feasibility, changing customer markets, and significant competitive threats from other companies.

At the date of acquisition, management began formulating integration plans which contemplate the closure of redundant facilities and the sale of certain businesses. In addition, the synergies created by joining the two organizations have resulted in employee terminations. The condensed consolidated balance sheet at November 2, 2002 reflects liabilities for such items; however, we will continue to finalize and announce other integration plans during fiscal 2003. The finalization of these integration plans concerning FSG’s facilities and employees will be reported in future periods as increases and decreases to goodwill and to the assets acquired and liabilities assumed. The November 2, 2002 condensed consolidated balance sheet reflects the preliminary allocation of the purchase price and goodwill of $170,109. The financial statement impact of integration plans that concern Pall facilities and employees will be reflected in earnings. Refer to Note 3 for discussion of actions taken in the first quarter of fiscal 2003. The goodwill related to the FSG acquisition is not tax deductible.

 

6


PALL CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)

(In thousands, except per share data)
(Unaudited)

The following table summarizes the preliminary allocation of the purchase price to the assets acquired and liabilities assumed:

Purchase price $ 367,801  
Transaction costs   7,033  
 

 
Total cost   374,834  
Cash acquired   19,671  
 

 
Total purchase price, net of cash acquired   355,163  
 

 
Current assets   164,453  
Property, plant and equipment   91,128  
Intangible assets   23,617  
Other non-current assets   3,900  
In-process research and development   37,600  
 

 
       
Total assets and in-process research and development acquired   320,698  
 

 
Current liabilities   101,144  
Non-current liabilities   34,500  
 

 
Total liabilities assumed   135,644  
 

 
Goodwill $ 170,109  
 

 

Goodwill has been allocated preliminarily to the Company’s reportable segments as follows:

BioPharmaceuticals $ 12,911  
General Industrial   136,121  
Microelectronics   21,077  
 

 
Total $ 170,109  
 

 

NOTE 3 – RESTRUCTURING AND OTHER CHARGES

The following table summarizes the restructuring related items and other charges recorded in the first quarter of fiscal 2003:

    Restructuring     Other
Charges and Adjustments
    Total Charged
To Earnings
    Adjustments to
Goodwill (a)
    Total  
 

 

 

 

 

 
In-process research and development (b) $   $  
37,600
  $  
37,600
  $  
  $  
37,600
 
Severance (c)   2,775         2,775     2,114     4,889  
Fixed asset write-offs (c)               451     451  
Office closures (c)               1,267     1,267  
Other (c)               487     487  
 

 

 

 

 

 
Total $ 2,775   $ 37,600   $ 40,375   $ 4,319   $ 44,694  
 

 

 

 

 

 
                               
Cash $ 2,775   $   $ 2,775   $ 3,868   $ 6,643  
Non-cash       37,600     37,600     451     38,051  
 

 

 

 

 

 
Total $ 2,775   $ 37,600   $ 40,375   $ 4,319   $ 44,694  
 

 

 

 

 

 

(a) Reflects restructuring activities related to FSG employees and facilities (refer to Note 2 for discussion of purchase accounting).
   
(b) In the first quarter of fiscal 2003, the Company recorded a charge of $37,600 for in-process research and development acquired in the acquisition of FSG. Please also refer to Note 2 for further discussion.
   
(c) At the date of the FSG acquisition, management began formulating integration plans and identifying synergistic opportunities. During the fourth quarter of fiscal 2002 and in the first quarter of fiscal 2003, the Company announced and implemented plans to eliminate redundant employees and facilities.

7


PALL CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)
(In thousands, except per share data)
(Unaudited)

  Furthermore, during the first quarter of fiscal 2003, the Company reorganized its Life Sciences business such that the Company’s hospital and medical OEM sub-segments were combined with the Blood segment to form a new segment called Pall Medical. Please refer to Note 8 for further information. This reorganization is expected to reduce costs and has resulted in the termination of employees globally.
   
  These actions resulted in the recording of approximately $4,889 in severance related liabilities for an estimated workforce reduction of 105 people, of which approximately 70 employees had been terminated in the first quarter of fiscal 2003. In addition, liabilities of approximately $1,754 were recorded principally for lease termination and other office closure costs. Fixed asset write-offs amounted to approximately $451 in the first quarter of fiscal 2003.
   
  Cash requirements of these actions are expected to be $6,643 of which $2,503 has been expended, leaving $4,140 in accruals reflected on the balance sheet as of November 2, 2002. The expected cash outlays comprise $4,889 in employee termination benefits and $1,754 principally related to lease termination liabilities and other office closure costs

The following table summarizes the activity in the first quarter of fiscal 2003 affecting the reserve balances related to restructuring actions taken in fiscal 2002 and fiscal 2003:

    Restructuring liabilities
recorded in:
       
 

       
    Fiscal 2003     Fiscal 2002     Total  
 

 

 

 
Balance at August 3, 2002
$   $ 10,424   $ 10,424  
Current year additions
  6,643         6,643  
Utilized
  (2,503 )   (6,101 )   (8,604 )
 

 

 

 
Balance at November 2, 2002
$ 4,140   $ 4,323   $ 8,463  
 

 

 

 

NOTE 4 – BALANCE SHEET DETAILS

The following tables provide details of selected balance sheet items:

    Nov. 2, 2002     Aug. 3, 2002  
 

 

 
Accounts receivable, net:
           
Accounts receivable
$ 377,328   $ 428,759  
Less: Allowances for doubtful accounts
  13,035     12,906  
 

 

 
Total
$ 364,293   $ 415,853  
 

 

 
Inventories:
           
Raw materials and components
$ 92,148   $ 90,807  
Work-in-process
  45,392     40,323  
Finished goods
  142,292     125,780  
 

 

 
Total
$ 279,832   $ 256,910  
 

 

 
             
Property, plant and equipment, net:
           
Property, plant and equipment
$ 1,134,093   $ 1,125,174  
Less: Accumulated depreciation and amortization
  534,506     520,079  
 

 

 
Total
$ 599,587   $ 605,095  
 

 

 

 

8


PALL CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)
(In thousands, except per share data)
(Unaudited)

NOTE 5 – NOTES PAYABLE AND LONG-TERM DEBT

On August 6, 2002, the Company completed an offering of $280,000 of 6% senior notes due on August 1, 2012. The notes are unsecured and unsubordinated obligations of the Company and rank pari passu to its other outstanding unsecured and unsubordinated indebtedness. On October 18, 2002, the Company entered into a $100,000 LIBOR based variable rate bank loan, which matures in quarterly installments of $5,000 starting in January 2003 through October 2007. The proceeds of the notes and loan were used to repay the interim credit facility taken to finance the FSG acquisition and for general corporate purposes.

On November 26, 2002, the Company terminated “receive fixed, pay variable” interest rate swaps relating to its $100,000 private placement of 7.83% unsecured senior notes due in 2010 and as a result the Company received $8,568. Simultaneously, the Company entered into new interest rate swaps involving the $280,000, 6% notes due on August 1, 2012. The new swaps require the Company to make payments at a variable rate based on LIBOR and receive payments at a fixed rate of 6% on notional amounts totaling $230,000.

NOTE 6 – GOODWILL AND INTANGIBLE ASSETS

The following table presents goodwill, net of accumulated amortization prior to the adoption of SFAS No. 142, allocated by reportable segment solely for purposes of SFAS No. 142 disclosure as of November 2, 2002 and August 3, 2002:

    Nov. 2, 2002     Aug. 3, 2002  
 

 

 
Medical $ 20,253   $ 19,512  
BioPharmaceuticals   27,866     31,423  
 

 

 
Life Sciences   48,119     50,935  
 

 

 
General Industrial   150,646     180,356  
Aerospace   6,122     6,038  
Microelectronics   21,214     25,644  
 

 

 
Industrial   177,982     212,038  
 

 

 
Total $ 226,101   $ 262,973  
 

 

 

The change in the carrying amount of goodwill is primarily attributable to the changes in the preliminary allocation of goodwill from the acquisition of FSG and to the translation of goodwill contained in the financial statements of foreign subsidiaries using the rates at each respective balance sheet date.

Intangible assets, net, consist of the following:

    Nov. 2, 2002     Aug. 3, 2002  
 

 

 
Patents and unpatented technology $ 78,167   $ 60,381  
Trademarks and other   9,363     9,605  
 

 

 
Subtotal   87,530     69,986  
Less: Accumulated amortization   32,192     30,038  
 

 

 
Total $ 55,338   $ 39,948  
 

 

 

Patents and trademarks include costs to register new patents and trademarks. Patents also include expenditures to successfully defend certain patents as well as for paid-up licenses for third-party patents. The increase in patents and unpatented technology is due to the finalization, in the first quarter of fiscal 2003, of the valuation of intangible assets purchased in the FSG acquisition. The fair values of these intangibles had not been determined as of August 3, 2002; as such, their cost had been preliminarily allocated based upon their book values.

Amortization expense for these intangible assets for the three months ended November 2, 2002 and October 27, 2001 was $1,957 and $1,194, respectively. Amortization expense is estimated to be approximately $5,623 for the remainder of fiscal 2003 and $7,300 in 2004, $5,600 in 2005 and $5,100 in 2006, 2007 and in 2008.

9


PALL CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)